Darzalex / Faspro
The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Darzalex / Faspro in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Darzalex / Faspro.
9
Global Revenue Ranking
7
2030 Global forecast Ranking
Recent articles on PMLiVE featuring Darzalex / Faspro
Support for first and only high-risk smouldering multiple myeloma treatment came from positive phase 3 trial results
The early precursor of active multiple myeloma accounts for around 15% of all new cases
The early precursor of active disease accounts for 15% of all newly-diagnosed multiple myeloma cases
The early precursor of active disease accounts for 15% of all newly-diagnosed multiple myeloma cases
More than 35,000 new cases of the blood cancer are expected to be diagnosed in the US this year
Data provided by GlobalData
GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.
Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.
To find out more about how our research and insights can help you, please visit https://www.globaldata.com/who-we-are/why-globaldata/
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology